ESRP2 and prostate carcinoma: The splicing patterns of NUMB exon 3, MYO1B exon 23 and other ESRP-target exons can be experimentally modulated either by depleting ESRP1 and ESRP2 protein levels in prostate cancer cells, or by using drugs like Casodex to interfere with AR signalling [30].